FDA 483 - Intercept Pharmaceuticals - February 01, 2016

An FDA inspection of Intercept Pharmaceuticals, Inc. in San Diego revealed significant deficiencies in clinical trial oversight. The firm failed to adequately monitor studies, retain essential records, and properly document the transfer of obligations to a contract research organization. These issues indicate a lack of robust controls over clinical trial conduct and data integrity.